logo

For the Inventor, By the Inventor

Zhejiang, China

Betta Pharmaceuticals Co., Ltd.

USPTO Granted Patents = 19

% Expired Patents = 36.8



Forward Citations = 17

Loading Chart...
Loading Chart...

37 inventors (with patents filed for the assignee):

goldMedal Lieming Ding (12 out of 14 patents)

silverMedal Shaojing Hu (11 out of 14 patents)

bronzeMedal Wei Long (11 out of 19 patents)

4.  Yinxiang Wang (8 out of 15 patents)

5.  Jiabing Wang (7 out of 8 patents)

6.  Fei Wang (7 out of 97 patents)

7.  Yanping Wang (4 out of 18 patents)

8.  Fenlai Tan (4 out of 8 patents)

9.  Yiqian Wang (3 out of 3 patents)

10.  Xiaofeng Xu (3 out of 4 patents)

11.  Yunyan Hu (3 out of 15 patents)

12.  Cunbo Ma (3 out of 9 patents)

13.  Hong Cao (3 out of 10 patents)

14.  Xiangyong Liu (3 out of 4 patents)

15.  Yan Xu (2 out of 53 patents)


19 patents:

1. 12187713 - Immunomodulators, compositions and methods thereof (2025-01-07),
2. 12043622 - Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof (2024-07-23),
3. 11845762 - Compound functioning as bromodomain protein inhibitor, and composition (2023-12-19),
4. 11466034 - Compound functioning as bromodomain protein inhibitor, and composition (2022-10-11),
5. 11466013 - ERK inhibitor and use thereof (2022-10-11),
6. 11365196 - FGFR inhibitor and application thereof (2022-06-21),
7. 11053238 - Benzimidazole derivatives, preparation methods and uses thereof (2021-07-06),
8. 10577364 - Crystalline form of fused pyridine derivative's maleate and uses thereof (2020-03-03),
9. 10059688 - Protein tyrosine kinase modulators and methods of use (2018-08-28),
10. 9783524 - Protein tyrosine kinase modulators and methods of use (2017-10-10),
11. 9688687 - Polymorphic forms of icotinib phosphate and uses thereof (2017-06-27),
12. 9617257 - Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors (2017-04-11),
13. 9611272 - Polymorphic forms of icotinib and uses thereof (2017-04-04),
14. 9505774 - Polymorphic forms of icotinib maleate and uses thereof (2016-11-29),
15. 9487570 - Glucagon like peptide analogs, composition, and method of use (2016-11-08),
Company Overview
Betta Pharmaceuticals Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in the research, development, and manufacturing of innovative therapeutic solutions. The company focuses on various domains, including oncology, respiratory diseases, and other critical health areas, aiming to enhance patient outcomes through advanced medical treatments. Headquartered in Zhejiang, China, Betta Pharmaceuticals is committed to leveraging cutting-edge technology and scientific expertise to address unmet medical needs and improve global health standards.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

19 Patents

#42 in Zhejiang

#1,553 in China

#32,693 in the World

Zhejiang, CN
Zhejiang, China

Betta Pharmaceuticals Co., Ltd.

Forward Citations = 17

37 inventors:

goldMedal Lieming Ding (12 out of 14 patents)

silverMedal Shaojing Hu (11 out of 14 patents)

bronzeMedal Wei Long (11 out of 19 patents)

4.  Yinxiang Wang (8 out of 15 patents)

5.  Jiabing Wang (7 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Betta Pharmaceuticals Co., Ltd.. Retrieved from https://idiyas.com/company/betta-pharmaceuticals-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…